Anaspec, Eurogentec Group, has released 11 MMP inhibitors - small molecules that act as either potent broad-spectrum inhibitors or selective inhibitors of MMPs.
They can be used as reference compounds for validating new MMP assays and/or for identifying novel MMP inhibitors.
Matrix metalloproteinases (MMPs) belong to a family of secreted or membrane-associated zinc endopeptidases capable of digesting extracellular matrix components.
They are involved in many aspects of both physiological processes and pathological conditions such as tumour development and metastasis, and rheumatoid arthritis.
As a result, compounds that inhibit MMP activity are considered promising therapeutic agents.
